9.78

2.41% 0.23

Pre-market: 9.68 -0.10 -1.02%

Immunitybio Inc (IBRX)

Overview News Price History Option Chain Financials Why IBRX Down? Discussions Forecast

Immunitybio Inc stock is traded at $9.78, with a volume of 28.92M. It is up +2.41% in the last 24 hours and up +64.37% over the past month. ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Previous Close:

$9.55

Open:

$9.41

24h Volume:

28.92M

Relative Volume:

0.90

Market Cap:

$9.63B

Revenue:

$1.31M

Net Income/Loss:

$-597.65M

P/E Ratio:

-10.08

EPS:

-0.97

Net Cash Flow:

$-425.62M

1W Performance:

+12.41%

1M Performance:

+64.37%

6M Performance:

+317.95%

1Y Performance:

+241.96%

1-Day Range:

$8.83

$9.80

1-Week Range:

$8.83

$12.43

52-Week Range:

$1.83

$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name

Immunitybio Inc

Sector

Healthcare (1110)

Industry

Biotechnology (620)

Phone

(844) 696-5235

Address

3530 JOHN HOPKINS COURT, SAN DIEGO

Employee

673

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IBRX Immunitybio Inc	9.78	9.41B	1.31M	-597.65M	-425.62M	-0.97
VRTX Vertex Pharmaceuticals Inc	496.83	121.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	781.67	81.49B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	766.92	47.74B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	332.92	43.93B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	316.99	35.67B	4.98B	69.60M	525.67M	0.5198

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-06-25	Initiated	H.C. Wainwright	Buy
Jan-10-25	Initiated	BTIG Research	Buy
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-03-22	Initiated	Jefferies	Buy

Immunitybio Inc Stock (IBRX) Latest News

Mar 01, 2026

Special Edition: Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Show 2/27 - ImmunityBio

Mar 01, 2026

Feb 28, 2026

ImmunityBio Stock Pre-Market (+6.5%): Phase 2 Trial Enrollment Completed Early - Trefis

Feb 28, 2026

Feb 27, 2026

ImmunityBio (NASDAQ:IBRX) Shares Up 2.4%Still a Buy? - MarketBeat

Feb 27, 2026

Key facts: ImmunityBio completes Phase 2 trial enrollment; conference call set - TradingView

Feb 27, 2026

Promising Biotech Stocks To ConsiderFebruary 27th - MarketBeat

Feb 27, 2026

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - BioSpace

Feb 27, 2026

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits

Feb 27, 2026

ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus - Yahoo Finance

Feb 27, 2026

IBRX Stock Price, Forecast & Analysis | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill

Feb 27, 2026

Feb 26, 2026

ImmunityBio (NASDAQ:IBRX) Director Sells $900,750.00 in Stock - MarketBeat

Feb 26, 2026

Simon, director, sells ImmunityBio (IBRX) shares worth $900k - Investing.com

Feb 26, 2026

Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum - Yahoo Finance

Feb 26, 2026

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up - Stocktwits

Feb 26, 2026

ImmunityBio completes enrollment in bladder cancer trial - Investing.com

Feb 26, 2026

ImmunityBio completes enrollment in bladder cancer trial By Investing.com - Investing.com UK

Feb 26, 2026

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Feb 26, 2026

ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High - Finviz

Feb 26, 2026

Patrick Soon-Shiong Reaffirms Control Over ImmunityBio with 66.3% Stake - Intellectia AI

Feb 26, 2026